NRGF-001

Activity Monitoring To Improve Patient Care During Chemoradiotherapy For Locally Advanced Non-small Cell Lung Cancer (La-nsclc)

Principal Investigator

Nitin Ohri, MD,

Status

Terminated

Disease Site

Lung [LU]

Non-small Cell Lung Cancer

Phase

I

Developmental Therapeutics

No

Primary Objective

To demonstrate that monitoring daily step counts during acourse of concurrent chemoradiotherapy for locally advanced non-small cell lungcancer will enable clinicians to deliver improved supportive care and reducethe rate of adverse clinical events during the radiotherapy course.

Patient Registration Portal

Click here to be redirected to the Patient Registration Portal for this study. Sites will need to access this link to register patients. 

Patient Population

Planned initiation (within the 30 days after study registration) of fractionated (≥15 treatments) thoracic radiotherapy with concurrent chemotherapy. Expected treatment scenarios include:

∙ Definitive treatment of stage III disease (most common)

∙ Definitive treatment for locoregional recurrence of early-stage disease

∙ Definitive treatment of unresectable stage II disease

∙ Preoperative treatment of stage III disease

∙ Postoperative treatment after incomplete resection (uncommon)

∙ Radical treatment for a patient with advanced/metastatic disease with the goal of achieving long-term thoracic disease control (e.g., oligometastatic disease where metastases are addressed with resection or stereotactic radiotherapy).

• Ambulates independently or with a cane.

Target Accrual

144